麻豆原创 Analysis and Insights: Global Cancer Biological Therapy 麻豆原创
The global Cancer Biological Therapy market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Cancer Biological Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Cancer Biological Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Cancer Biological Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Cancer Biological Therapy include ELI Lilly, Sanofi, Merck, Bayer, Roche, Novartis International, Pfizer, Bristol-Myers Squibb and Seattle Genetics, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Cancer Biological Therapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Cancer Biological Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cancer Biological Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cancer Biological Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Cancer Biological Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Cancer Biological Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ELI Lilly, Sanofi, Merck, Bayer, Roche, Novartis International, Pfizer, Bristol-Myers Squibb and Seattle Genetics, etc.
By Company
ELI Lilly
Sanofi
Merck
Bayer
Roche
Novartis International
Pfizer
Bristol-Myers Squibb
Seattle Genetics
Amgen
Takeda Pharmaceuticals
GlaxoSmithKline
Spectrum Pharmaceuticals
Celgene Corporation
AstraZeneca, Plc.
Otsuka
Eisai
Abbvie
Incyte
Segment by Type
Monoclonal Antibodies
Vaccines
Cancer Growth Blockers
Blood Cell Growth Factors
Segment by Application
Hospitals
Diagnostic Laboratories
Research & Academic Laboratories
Pharmaceutical & Biotechnology Companies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cancer Biological Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biological Therapy companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Biological Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cancer Biological Therapy 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.2.4 Cancer Growth Blockers
1.2.5 Blood Cell Growth Factors
1.3 麻豆原创 by Application
1.3.1 Global Cancer Biological Therapy 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Diagnostic Laboratories
1.3.4 Research & Academic Laboratories
1.3.5 Pharmaceutical & Biotechnology Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biological Therapy 麻豆原创 Perspective (2018-2029)
2.2 Global Cancer Biological Therapy Growth Trends by Region
2.2.1 Cancer Biological Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Biological Therapy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cancer Biological Therapy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cancer Biological Therapy 麻豆原创 Dynamics
2.3.1 Cancer Biological Therapy Industry Trends
2.3.2 Cancer Biological Therapy 麻豆原创 Drivers
2.3.3 Cancer Biological Therapy 麻豆原创 Challenges
2.3.4 Cancer Biological Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Cancer Biological Therapy by Players
3.1.1 Global Cancer Biological Therapy Revenue by Players (2018-2023)
3.1.2 Global Cancer Biological Therapy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cancer Biological Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Cancer Biological Therapy, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Cancer Biological Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Biological Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biological Therapy Revenue in 2022
3.5 Global Key Players of Cancer Biological Therapy Head office and Area Served
3.6 Global Key Players of Cancer Biological Therapy, Product and Application
3.7 Global Key Players of Cancer Biological Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biological Therapy Breakdown Data by Type
4.1 Global Cancer Biological Therapy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cancer Biological Therapy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cancer Biological Therapy Breakdown Data by Application
5.1 Global Cancer Biological Therapy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cancer Biological Therapy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cancer Biological Therapy 麻豆原创 Size (2018-2029)
6.2 North America Cancer Biological Therapy 麻豆原创 Size by Type
6.2.1 North America Cancer Biological Therapy 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Cancer Biological Therapy 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Cancer Biological Therapy 麻豆原创 Share by Type (2018-2029)
6.3 North America Cancer Biological Therapy 麻豆原创 Size by Application
6.3.1 North America Cancer Biological Therapy 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Cancer Biological Therapy 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Cancer Biological Therapy 麻豆原创 Share by Application (2018-2029)
6.4 North America Cancer Biological Therapy 麻豆原创 Size by Country
6.4.1 North America Cancer Biological Therapy 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Cancer Biological Therapy 麻豆原创 Size (2018-2029)
7.2 Europe Cancer Biological Therapy 麻豆原创 Size by Type
7.2.1 Europe Cancer Biological Therapy 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Cancer Biological Therapy 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Cancer Biological Therapy 麻豆原创 Share by Type (2018-2029)
7.3 Europe Cancer Biological Therapy 麻豆原创 Size by Application
7.3.1 Europe Cancer Biological Therapy 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Cancer Biological Therapy 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Cancer Biological Therapy 麻豆原创 Share by Application (2018-2029)
7.4 Europe Cancer Biological Therapy 麻豆原创 Size by Country
7.4.1 Europe Cancer Biological Therapy 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Cancer Biological Therapy 麻豆原创 Size (2018-2029)
8.2 China Cancer Biological Therapy 麻豆原创 Size by Type
8.2.1 China Cancer Biological Therapy 麻豆原创 Size by Type (2018-2023)
8.2.2 China Cancer Biological Therapy 麻豆原创 Size by Type (2024-2029)
8.2.3 China Cancer Biological Therapy 麻豆原创 Share by Type (2018-2029)
8.3 China Cancer Biological Therapy 麻豆原创 Size by Application
8.3.1 China Cancer Biological Therapy 麻豆原创 Size by Application (2018-2023)
8.3.2 China Cancer Biological Therapy 麻豆原创 Size by Application (2024-2029)
8.3.3 China Cancer Biological Therapy 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cancer Biological Therapy 麻豆原创 Size (2018-2029)
9.2 Asia Cancer Biological Therapy 麻豆原创 Size by Type
9.2.1 Asia Cancer Biological Therapy 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Cancer Biological Therapy 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Cancer Biological Therapy 麻豆原创 Share by Type (2018-2029)
9.3 Asia Cancer Biological Therapy 麻豆原创 Size by Application
9.3.1 Asia Cancer Biological Therapy 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Cancer Biological Therapy 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Cancer Biological Therapy 麻豆原创 Share by Application (2018-2029)
9.4 Asia Cancer Biological Therapy 麻豆原创 Size by Region
9.4.1 Asia Cancer Biological Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Cancer Biological Therapy 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Cancer Biological Therapy 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 ELI Lilly
11.1.1 ELI Lilly Company Details
11.1.2 ELI Lilly Business Overview
11.1.3 ELI Lilly Cancer Biological Therapy Introduction
11.1.4 ELI Lilly Revenue in Cancer Biological Therapy Business (2018-2023)
11.1.5 ELI Lilly Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Cancer Biological Therapy Introduction
11.2.4 Sanofi Revenue in Cancer Biological Therapy Business (2018-2023)
11.2.5 Sanofi Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Cancer Biological Therapy Introduction
11.3.4 Merck Revenue in Cancer Biological Therapy Business (2018-2023)
11.3.5 Merck Recent Developments
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Cancer Biological Therapy Introduction
11.4.4 Bayer Revenue in Cancer Biological Therapy Business (2018-2023)
11.4.5 Bayer Recent Developments
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Cancer Biological Therapy Introduction
11.5.4 Roche Revenue in Cancer Biological Therapy Business (2018-2023)
11.5.5 Roche Recent Developments
11.6 Novartis International
11.6.1 Novartis International Company Details
11.6.2 Novartis International Business Overview
11.6.3 Novartis International Cancer Biological Therapy Introduction
11.6.4 Novartis International Revenue in Cancer Biological Therapy Business (2018-2023)
11.6.5 Novartis International Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Cancer Biological Therapy Introduction
11.7.4 Pfizer Revenue in Cancer Biological Therapy Business (2018-2023)
11.7.5 Pfizer Recent Developments
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Cancer Biological Therapy Introduction
11.8.4 Bristol-Myers Squibb Revenue in Cancer Biological Therapy Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Developments
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Details
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Cancer Biological Therapy Introduction
11.9.4 Seattle Genetics Revenue in Cancer Biological Therapy Business (2018-2023)
11.9.5 Seattle Genetics Recent Developments
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Cancer Biological Therapy Introduction
11.10.4 Amgen Revenue in Cancer Biological Therapy Business (2018-2023)
11.10.5 Amgen Recent Developments
11.11 Takeda Pharmaceuticals
11.11.1 Takeda Pharmaceuticals Company Details
11.11.2 Takeda Pharmaceuticals Business Overview
11.11.3 Takeda Pharmaceuticals Cancer Biological Therapy Introduction
11.11.4 Takeda Pharmaceuticals Revenue in Cancer Biological Therapy Business (2018-2023)
11.11.5 Takeda Pharmaceuticals Recent Developments
11.12 GlaxoSmithKline
11.12.1 GlaxoSmithKline Company Details
11.12.2 GlaxoSmithKline Business Overview
11.12.3 GlaxoSmithKline Cancer Biological Therapy Introduction
11.12.4 GlaxoSmithKline Revenue in Cancer Biological Therapy Business (2018-2023)
11.12.5 GlaxoSmithKline Recent Developments
11.13 Spectrum Pharmaceuticals
11.13.1 Spectrum Pharmaceuticals Company Details
11.13.2 Spectrum Pharmaceuticals Business Overview
11.13.3 Spectrum Pharmaceuticals Cancer Biological Therapy Introduction
11.13.4 Spectrum Pharmaceuticals Revenue in Cancer Biological Therapy Business (2018-2023)
11.13.5 Spectrum Pharmaceuticals Recent Developments
11.14 Celgene Corporation
11.14.1 Celgene Corporation Company Details
11.14.2 Celgene Corporation Business Overview
11.14.3 Celgene Corporation Cancer Biological Therapy Introduction
11.14.4 Celgene Corporation Revenue in Cancer Biological Therapy Business (2018-2023)
11.14.5 Celgene Corporation Recent Developments
11.15 AstraZeneca, Plc.
11.15.1 AstraZeneca, Plc. Company Details
11.15.2 AstraZeneca, Plc. Business Overview
11.15.3 AstraZeneca, Plc. Cancer Biological Therapy Introduction
11.15.4 AstraZeneca, Plc. Revenue in Cancer Biological Therapy Business (2018-2023)
11.15.5 AstraZeneca, Plc. Recent Developments
11.16 Otsuka
11.16.1 Otsuka Company Details
11.16.2 Otsuka Business Overview
11.16.3 Otsuka Cancer Biological Therapy Introduction
11.16.4 Otsuka Revenue in Cancer Biological Therapy Business (2018-2023)
11.16.5 Otsuka Recent Developments
11.17 Eisai
11.17.1 Eisai Company Details
11.17.2 Eisai Business Overview
11.17.3 Eisai Cancer Biological Therapy Introduction
11.17.4 Eisai Revenue in Cancer Biological Therapy Business (2018-2023)
11.17.5 Eisai Recent Developments
11.18 Abbvie
11.18.1 Abbvie Company Details
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Cancer Biological Therapy Introduction
11.18.4 Abbvie Revenue in Cancer Biological Therapy Business (2018-2023)
11.18.5 Abbvie Recent Developments
11.19 Incyte
11.19.1 Incyte Company Details
11.19.2 Incyte Business Overview
11.19.3 Incyte Cancer Biological Therapy Introduction
11.19.4 Incyte Revenue in Cancer Biological Therapy Business (2018-2023)
11.19.5 Incyte Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ELI Lilly
Sanofi
Merck
Bayer
Roche
Novartis International
Pfizer
Bristol-Myers Squibb
Seattle Genetics
Amgen
Takeda Pharmaceuticals
GlaxoSmithKline
Spectrum Pharmaceuticals
Celgene Corporation
AstraZeneca, Plc.
Otsuka
Eisai
Abbvie
Incyte
听
听
*If Applicable.
